(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Eyepoint Pharmaceuticals's revenue in 2024 is $50,019,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2024 to be $2,357,182,559, with the lowest EYPT revenue forecast at $1,689,096,281, and the highest EYPT revenue forecast at $2,864,640,625. On average, 4 Wall Street analysts forecast EYPT's revenue for 2025 to be $746,108,672, with the lowest EYPT revenue forecast at $156,253,125, and the highest EYPT revenue forecast at $1,239,608,125.
In 2026, EYPT is forecast to generate $338,548,438 in revenue, with the lowest revenue forecast at $156,253,125 and the highest revenue forecast at $520,843,750.